[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]

[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]

Tamoxifen administered in patients after breast cancer surgery is one of the most effective adjuvant treatments in this pathology. A large number of randomized studies including thousands of patients allowed to quantify the treatment benefits in terms of recurrence, contralateral breast cancer and o...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Davies, C, Arriagada, R, Ziegler, A, Peralta, O
Formaat:	Journal article
Taal:	Spanish; Castilian
Gepubliceerd in:	1998

Gelijkaardige items

Variation in use of adjuvant tamoxifen.
door: Davies, C, et al.
Gepubliceerd in: (1998)

[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed]
door: Davies, C, et al.
Gepubliceerd in: (1997)

Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.
door: Earl, H, et al.
Gepubliceerd in: (1996)

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
door: Early Breast Cancer Trialists' Collaborative Group
Gepubliceerd in: (1988)

Tamoxifen therapy for patients with breast cancer - Authors' reply.
door: Davies, C, et al.
Gepubliceerd in: (2013)

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
door: Dowsett, M, et al.
Gepubliceerd in: (2009)

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
door: Gelber, R, et al.
Gepubliceerd in: (1996)

Adjuvant treatment for breast cancer
door: Flatley, M, et al.
Gepubliceerd in: (2019)

Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy
door: Lim, I-Liang, et al.
Gepubliceerd in: (2018)

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.
door: Davies, C
Gepubliceerd in: (2004)

Early breast cancer: How long should tamoxifen continue?
door: Davies, C, et al.
Gepubliceerd in: (1999)

WITHDRAWN: Tamoxifen for early breast cancer.
door: Clarke, M
Gepubliceerd in: (2008)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
door: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Gepubliceerd in: (2011)

Which adjuvant endocrine therapy for ER-positive non-metastatic breast cancer? EBCTCG-2000 update: Tamoxifen, castration, LHRH-agonists
door: Davies, C, et al.
Gepubliceerd in: (2002)

Early breast cancer: How long should tamoxifen continue?
door: Davies, C, et al.
Gepubliceerd in: (1998)

Tamoxifen for early breast cancer: better late than never.
door: Gray, R, et al.
Gepubliceerd in: (2000)

Update of the worldwide evidence on the adjuvant treatment of breast cancer
door: Peto, R, et al.
Gepubliceerd in: (2002)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
door: Mele, T, et al.
Gepubliceerd in: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
door: Mele, T, et al.
Gepubliceerd in: (2010)

Tamoxifen in breast conservation therapy.
door: Lee, K, et al.
Gepubliceerd in: (1995)

Tamoxifen for early breast cancer: an overview of the randomised trials
door: Early Breast Cancer Trialists' Collaborative Group
Gepubliceerd in: (1998)

EFFECTS OF ADJUVANT TAMOXIFEN AND OF CYTOTOXIC THERAPY ON MORTALITY IN EARLY BREAST-CANCER - AN OVERVIEW OF 61 RANDOMIZED TRIALS AMONG 28,896 WOMEN
door: Peto, R
Gepubliceerd in: (1989)

10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS
door: Davies, C, et al.
Gepubliceerd in: (2017)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
door: Davies, C, et al.
Gepubliceerd in: (2013)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
door: Davies, C, et al.
Gepubliceerd in: (2013)

THE EBCTCG OVERVIEW OF ADJUVANT THERAPY OF BREAST-CANCER
door: Gray, R, et al.
Gepubliceerd in: (1994)

Adjuvant! online is overoptimistic in predicting survival of Asian breast cancer patients
door: Bhoo-Pathy, N., et al.
Gepubliceerd in: (2012)

Nordamnacanthal potentiates the cytotoxic effects of tamoxifen in human breast cancer cells
door: Mohamed Alitheen, Noorjahan Banu, et al.
Gepubliceerd in: (2015)

Genetic Polymorphism of CYP2D6 and MDR1 in breast cancer patients treated with tamoxifen
door: Mohamad, NI, et al.
Gepubliceerd in: (2010)

Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
door: Kerr, AJ, et al.
Gepubliceerd in: (2022)

Cognitive function in women with early breast cancer receiving adjuvant chemotherapy
door: Lacey, RT, et al.
Gepubliceerd in: (2006)

VATS lobectomy facilitates delivery of adjuvant chemotherapy following NSCLC resection
door: Abah, U, et al.
Gepubliceerd in: (2012)

Evaluation of optic nerve head parameters and visual evoked potential among breast cancer patients on tamoxifen
door: Lee, Tan Chai
Gepubliceerd in: (2017)

Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen
door: Hermawan, Adam, et al.
Gepubliceerd in: (2022)

Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen
door: Goss, P, et al.
Gepubliceerd in: (2009)

Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer.
door: Cuzick, J, et al.
Gepubliceerd in: (1987)

Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
door: Gasparini, G, et al.
Gepubliceerd in: (1995)

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
door: Lipplaa, A, et al.
Gepubliceerd in: (2018)

Tamoxifen-loaded solid lipid nanoparticles-induced apoptosis in breast cancer cell lines
door: Abbasalipourkabirreh, Roghayeh, et al.
Gepubliceerd in: (2016)

What is the risk of cardiac morbidity with adjuvant radiotherapy for breast cancer?
door: Vallis, K
Gepubliceerd in: (2006)